Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

Wristwatch-like devices detect early signs of Alzheimer’s

Monitoring daily activity patterns using a wrist-worn device may detect early warning signs of Alzheimer’s disease, according to a new study led by researchers at

March 11, 2024

Health workers fear it’s profits before protection as CDC revisits airborne transmission

Four years after hospitals in New York City overflowed with covid-19 patients, emergency physician Sonya Stokes remains shaken by how unprepared and misguided the American

March 19, 2024

Developing high-potent APIs: The necessary steps to follow – Pharmaceutical Technology

Rigorous measures need to be in place to protect clinical staff from toxic HPAPIs. Image credit: Gorodenkoff The demand for high-potency active pharmaceutical ingredients (HPAPIs)

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.